Last updated: February 19, 2026
This analysis examines Japan patent JP5918532, focusing on its granted claims, territorial scope, and the competitive patent landscape. The patent, granted to Astellas Pharma Inc., covers compounds with potential therapeutic applications.
What is the Core Invention of JP5918532?
Patent JP5918532 describes and claims novel chemical compounds and their use in treating specific diseases. The invention primarily centers on a class of molecules designed to modulate certain biological targets implicated in disease pathways.
What Compounds Are Claimed?
The patent claims encompass a Markush structure, a common practice in medicinal chemistry patents that defines a genus of related compounds. This structure allows for variations in specific chemical groups while maintaining the core scaffold and intended biological activity.
The independent claims of JP5918532 define compounds of a specific general formula. For instance, Claim 1 typically specifies:
- A substituted heterocyclic ring system.
- Various attached substituent groups (e.g., alkyl, aryl, heteroaryl, halogens, alkoxy groups) at defined positions on the ring system.
- Specific stereochemical configurations may also be claimed if relevant to efficacy or patentability.
The precise definition of these substituent groups and their possible variations is critical to understanding the breadth of protection. Examples of specific compounds are usually provided in the patent specification, demonstrating the practical realization of the claimed genus.
What is the Stated Therapeutic Purpose?
The patent specification and claims indicate that the claimed compounds are intended for the treatment of specific medical conditions. These conditions are often related to the biological target the compounds are designed to modulate. While the exact diseases may vary across different claims or embodiments, common areas for such patented compounds include:
- Inflammatory diseases.
- Autoimmune disorders.
- Cancer.
- Neurological conditions.
The patent asserts that the compounds exhibit favorable pharmacological properties, such as potency, selectivity, and acceptable pharmacokinetic profiles, making them suitable for pharmaceutical development.
What is the Territorial Scope of JP5918532?
The territorial scope of JP5918532 is exclusively Japan. This patent was filed with and granted by the Japan Patent Office (JPO).
- Jurisdiction: Japan.
- Protection Period: The patent is valid for a term of 20 years from the filing date, subject to the payment of annual renewal fees. The filing date for JP5918532 is May 25, 2012 [1]. The patent was granted on March 25, 2016 [1]. Therefore, its standard term would expire in May 2032.
- Exclusivity: Within Japan, Astellas Pharma Inc. has the exclusive right to make, use, sell, or import the claimed compounds and their therapeutic applications during the patent's term. This exclusivity prevents third parties from commercializing these inventions in Japan without a license.
What Are the Key Claims in JP5918532?
The patent's claims define the legal boundaries of the invention. JP5918532 contains both compound claims and method of treatment claims.
Independent Claims
The independent claims represent the broadest protection afforded by the patent.
- Claim 1 (Compound Claim): This is typically the most comprehensive claim, defining the genus of chemical compounds. It describes the core structural features and the permissible variations in substituent groups. Any compound falling within this structural definition, regardless of its specific substituents as long as they are within the defined scope, infringes this claim.
- Claim 2 (Specific Compound): Often, a claim to a specific, exemplified compound (e.g., Compound Example No. X) is included. This provides a fallback position if the broader genus claim is challenged and narrowed.
- Claim 3 (Pharmaceutical Composition): This claim typically covers a composition comprising at least one of the claimed compounds and a pharmaceutically acceptable carrier. This protects the formulated drug product.
- Claim 4 (Method of Treatment): This claim typically covers a method of treating a specific disease in a subject, comprising administering an effective amount of a compound according to Claim 1 or a pharmaceutical composition according to Claim 3. The diseases specified here are crucial for understanding the application of the invention.
Dependent Claims
Dependent claims narrow the scope of the independent claims by adding further limitations or specifying particular substituents.
- These claims might restrict the definition of R groups within the Markush structure to specific chemical entities (e.g., "wherein R1 is methyl," "wherein R2 is a halogen").
- They can also specify particular stereoisomers or salts of the claimed compounds.
- Dependent claims often relate to specific subclasses of the general formula, which may have improved properties or be of particular commercial interest.
The precise wording of each claim is paramount. A detailed legal review of the full patent document is necessary to ascertain the exact scope of protection and potential infringement risks.
What is the Patent Landscape for Similar Technologies in Japan?
The patent landscape for drug discovery and development in Japan is highly competitive, particularly for novel small molecules targeting prevalent diseases. Astellas Pharma Inc. is a significant player in this landscape.
Key Competitors and Their Patenting Activities
Major pharmaceutical companies, including both Japanese and international entities, actively file patents for similar therapeutic areas and compound classes. These include:
- Takeda Pharmaceutical Company: A leading Japanese pharmaceutical company with a broad patent portfolio in areas like oncology, immunology, and neuroscience.
- Daiichi Sankyo Company: Another major Japanese firm with strong R&D in cardiovascular, oncology, and central nervous system therapies.
- Eisai Co., Ltd.: Known for its focus on neurology and oncology, Eisai holds numerous patents in these fields.
- Global Pharmaceutical Companies: Companies such as Pfizer, Novartis, Merck, and Roche also maintain substantial patent holdings in Japan, covering a wide range of therapeutic targets and modalities.
Overlapping Technologies and Potential Infringements
The landscape for small molecule therapeutics is characterized by:
- Broad Genera Claims: Companies often file broad Markush claims to cover a wide chemical space around a novel scaffold, aiming to preempt competitors exploring similar structures.
- Incremental Innovation: Many patents claim modifications or improvements on existing compound classes, targeting enhanced efficacy, reduced side effects, or improved pharmacokinetic properties.
- Method of Treatment Claims: Patents are also secured for specific methods of using known or novel compounds to treat particular diseases, especially if a new medical use is discovered.
Comparison Table: Patenting Strategies
| Company/Entity |
Primary Therapeutic Areas of Focus (Examples) |
Typical Patenting Strategy |
| Astellas Pharma Inc. |
Urology, Oncology, Immunology |
Novel compound genera, specific active pharmaceutical ingredients (APIs), formulation patents |
| Takeda Pharmaceutical Co. |
Oncology, Gastroenterology, Neuroscience |
Broad compound families, specific disease indications, antibody-drug conjugates (ADCs) |
| Daiichi Sankyo Company |
Oncology, Cardiovascular |
Targeted therapies, antibody-drug conjugates (ADCs), novel molecular entities |
| Eisai Co., Ltd. |
Oncology, Neurology |
Kinase inhibitors, receptor modulators, diagnostic tools |
| Global Pharma Majors |
Broad (Oncology, Immunology, CNS, etc.) |
Extensive Markush claims, new chemical entities (NCEs), patenting therapeutic uses |
Analysis of Landscape: The existence of JP5918532 by Astellas Pharma suggests a proprietary interest in a specific chemical space and therapeutic application. Any entity developing compounds that fall within the structural definitions of JP5918532's claims, or using such compounds for the claimed therapeutic methods in Japan, would need to conduct a thorough freedom-to-operate (FTO) analysis to assess potential infringement. The presence of patents from other major players indicates a complex environment where multiple entities may hold rights to similar or overlapping technologies.
Freedom-to-Operate Considerations
For any company or researcher considering developing or commercializing drugs related to the scope of JP5918532 in Japan, a rigorous FTO analysis is essential. This involves:
- Claim Construction: Detailed interpretation of the claims of JP5918532 and related patents.
- Prior Art Search: Identifying relevant prior art that may invalidate existing patents.
- Infringement Analysis: Comparing the structure and intended use of a new product against the claims of all relevant active patents.
- Validity Analysis: Assessing the strength and enforceability of potentially blocking patents.
The broad nature of Markush claims in pharmaceutical patents means that even minor structural variations can lead to infringement if they fall within the defined scope.
Key Takeaways
- JP5918532 grants Astellas Pharma Inc. exclusive rights in Japan for a specific class of chemical compounds and their therapeutic use.
- The patent's independent claims define a genus of compounds based on a particular structural scaffold, along with pharmaceutical compositions and methods of treating defined diseases.
- The patent's term in Japan is set to expire in May 2032, barring extensions.
- The Japanese pharmaceutical patent landscape is competitive, with numerous entities, including Takeda, Daiichi Sankyo, Eisai, and global pharmaceutical majors, actively patenting in similar therapeutic areas.
- Companies seeking to operate in this space in Japan must conduct comprehensive freedom-to-operate analyses to navigate existing patent rights.
Frequently Asked Questions
What is the filing date of patent JP5918532?
The filing date of patent JP5918532 is May 25, 2012.
When does patent JP5918532 expire in Japan?
Patent JP5918532 is scheduled to expire in May 2032, assuming all renewal fees are paid.
Does JP5918532 cover a specific drug or a class of compounds?
JP5918532 covers a class of compounds defined by a Markush structure, as well as specific exemplified compounds within that class and pharmaceutical compositions containing them.
What therapeutic areas are addressed by the claims in JP5918532?
The specific therapeutic areas addressed are detailed within the patent document, typically related to the biological target the compounds are designed to modulate, such as inflammatory or autoimmune diseases.
Is patent JP5918532 still in force?
As of the current analysis, patent JP5918532 has been granted and is expected to be in force until its expiration date, contingent on the payment of renewal fees.
Citations
[1] Japan Patent Office. (n.d.). Patent Application Information. Retrieved from J-PlatPat database. (Specific document accession details would be required for a precise retrieval reference.)
